Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II capecitabine monotherapy in platinum-resistant or platinum-refractory ovarian cancer
2006-001724-40Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in ovarian cancer, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Response rate. Started Jun 2006; status: completed.
02
Drugs
capecitabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2006-001724-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001724-40.